GLUT1 expression in pediatric adrenocortical tumors: a promising candidate to predict clinical behavior

Imagem de Miniatura
Arquivos
art_PINHEIRO_GLUT1_expression_in_pediatric_adrenocortical_tumors_a_promising_2017.PDF (3.56 MB)
Citações na Scopus
9
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
IMPACT JOURNALS LLC
Autores
PINHEIRO, Celine
GRANJA, Sara
BONATELLI, Murilo
COSTA, Ricardo F. A.
LERARIO, Antonio M.
Citação
ONCOTARGET, v.8, n.38, p.63835-63845, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Discrimination between benign and malignant tumors is a challenging process in pediatric adrenocortical tumors. New insights in the metabolic profile of pediatric adrenocortical tumors may contribute to this distinction, predict prognosis, as well as identify new molecular targets for therapy. The aim of this work is to characterize the expression of the metabolism-related proteins MCT1, MCT2, MCT4, CD147, CD44, GLUT1 and CAIX in a series of pediatric adrenocortical tumors. Methods: A total of 50 pediatric patients presenting adrenocortical tumors, including 41 clinically benign and 9 clinically malignant tumors, were included. Protein expression was evaluated using immunohistochemistry in samples arranged in tissue microarrays. Results: The immunohistochemical analysis showed a significant increase in plasma membrane expression of GLUT1 in malignant lesions, when compared to benign lesions (p=0.004), being the expression of this protein associated with shorter overall and disease-free survival (p=0.004 and p=0.001, respectively). Although significant differences were not observed for proteins other than GLUT1, MCT1, MCT4 and CD147 were highly expressed in pediatric adrenocortical neoplasias (around 90%). Conclusion: GLUT1 expression was differentially expressed in pediatric adrenocortical tumors, with higher expression in clinically malignant tumors, and associated with shorter survival, suggesting a metabolic remodeling towards a hyperglycolytic phenotype in this malignancy.
Palavras-chave
pediatric adrenocortical tumors, metabolic reprogramming, monocarboxylate transporter, glucose transporter, Warburg effect
URI
https://observatorio.fm.usp.br/handle/OPI/22022
Referências
  1. Almeida MQ, 2008, J CLIN ENDOCR METAB, V93, P3524, DOI 10.1210/jc.2008-0065
  2. Amann T, 2009, EXPERT OPIN THER TAR, V13, P1411, DOI 10.1517/14728220903307509
  3. Baltazar F, 2014, HISTOL HISTOPATHOL, V29, P1511, DOI 10.14670/HH-29.1511
  4. Bourdeau I, 2013, CURR OPIN ENDOCRINOL, V20, P192, DOI 10.1097/MED.0b013e3283602274
  5. Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981
  6. Chan DA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002394
  7. Chatterjee G, 2015, PEDIATR SURG INT, V31, P563, DOI 10.1007/s00383-015-3708-x
  8. Chiche J, 2010, J CELL MOL MED, V14, P771, DOI 10.1111/j.1582-4934.2009.00994.x
  9. Cistaro A, 2015, HELL J NUCL MED, V18, P97, DOI 10.1967/s002449910202
  10. Custodio G, 2012, MOL CELL ENDOCRINOL, V351, P44, DOI 10.1016/j.mce.2011.10.019
  11. Deandreis Desiree, 2011, Hormones & Cancer, V2, P354, DOI 10.1007/s12672-011-0091-5
  12. Else T, 2014, ENDOCR REV, V35, P282, DOI 10.1210/er.2013-1029
  13. Faria AM, 2012, MOL CELL ENDOCRINOL, V351, P52, DOI 10.1016/j.mce.2011.09.040
  14. Fassnacht M, 2013, J CLIN ENDOCR METAB, V98, P4551, DOI 10.1210/jc.2013-3020
  15. Fassnacht M, 2011, NAT REV ENDOCRINOL, V7, P323, DOI 10.1038/nrendo.2010.235
  16. Fassnacht M, 2009, CANCER, V115, P243, DOI 10.1002/cncr.24030
  17. Fenske W, 2009, ENDOCR-RELAT CANCER, V16, P919, DOI 10.1677/ERC-08-0211
  18. Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
  19. Gillies RJ, 2015, CANCER J, V21, P88, DOI 10.1097/PPO.0000000000000102
  20. Granja S, 2015, CURR DRUG METAB, V16, P221, DOI 10.2174/1389200216666150602145145
  21. Granja S, 2013, CELL PHYSIOL BIOCHEM, V32, P1845, DOI 10.1159/000356617
  22. Grumbach MM, 2003, ANN INTERN MED, V138, P424
  23. Gulack BC, 2016, J PEDIATR SURG, V51, P172, DOI 10.1016/j.jpedsurg.2015.10.039
  24. Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
  25. Hanna AM, 2008, J PEDIATR SURG, V43, P843, DOI 10.1016/j.jpedsurg.2007.12.022
  26. Imperiale A, 2013, ENDOCR-RELAT CANCER, V20, P705, DOI 10.1530/ERC-13-0232
  27. Kjellin H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087951
  28. Klein JD, 2011, J PEDIATR SURG, V46, P1201, DOI 10.1016/j.jpedsurg.2011.03.052
  29. Kreissig R, 2000, PEDIATR RADIOL, V30, P306, DOI 10.1007/s002470050745
  30. Kuhajda FP, 2008, INT J OBESITY, V32, pS36, DOI 10.1038/ijo.2008.121
  31. Lalli E, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00023
  32. Latronico AC, 2001, J CLIN ENDOCR METAB, V86, P4970, DOI 10.1210/jc.86.10.4970
  33. Liu W, 2014, ASIAN PAC J CANCER P, V15, P7037, DOI 10.7314/APJCP.2014.15.17.7037
  34. Lucon Antonio Marmo, 2002, Rev. Hosp. Clin., V57, P251, DOI 10.1590/S0041-87812002000600002
  35. McAteer JP, 2013, J PEDIATR SURG, V48, P1025, DOI 10.1016/j.jpedsurg.2013.02.017
  36. MENDONCA BB, 1995, J UROLOGY, V154, P2004, DOI 10.1016/S0022-5347(01)66673-4
  37. Michalkiewicz E, 2004, J CLIN ONCOL, V22, P838, DOI 10.1200/JCO.2004.08.085
  38. Murphy JJ, 2008, J PEDIATR SURG, V43, P2186, DOI 10.1016/j.jpedsurg.2008.08.064
  39. Nagarajan Arvindhan, 2016, Trends Cancer, V2, P365
  40. Nunes ML, 2010, WORLD J SURG, V34, P1506, DOI 10.1007/s00268-010-0576-3
  41. Papotti Mauro, 2011, Hormones & Cancer, V2, P333, DOI 10.1007/s12672-011-0088-0
  42. Lira RCP, 2016, ENDOCR-RELAT CANCER, V23, P481, DOI 10.1530/ERC-15-0426
  43. Pinheiro C, 2008, VIRCHOWS ARCH, V452, P139, DOI 10.1007/s00428-007-0558-5
  44. Pinheiro C, 2015, ONCOTARGET, V6, P44403, DOI 10.18632/oncotarget.5623
  45. Pinheiro C, 2011, HISTOL HISTOPATHOL, V26, P1279, DOI 10.14670/HH-26.1279
  46. Pinheiro C, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/427694
  47. Pinto Emilia M., 2004, Arq Bras Endocrinol Metab, V48, P647, DOI 10.1590/S0004-27302004000500009
  48. Queiros O, 2012, J BIOENERG BIOMEMBR, V44, P141, DOI 10.1007/s10863-012-9418-3
  49. Ribeiro RC, 2001, P NATL ACAD SCI USA, V98, P9330, DOI 10.1073/pnas.161479898
  50. Sandrini R, 1997, J CLIN ENDOCR METAB, V82, P2027, DOI 10.1210/jc.82.7.2027
  51. Satoh K, 2015, ANN SURG ONCOL, V22, pS714, DOI 10.1245/s10434-015-4813-8
  52. Shang YL, 2008, MOL CANCER THER, V7, P2599, DOI 10.1158/1535-7163.MCT-07-2401
  53. Stewart JN, 2004, J PEDIATR SURG, V39, P759, DOI 10.1016/j.jpedsurg.2004.01.029
  54. Takeuchi S, 2014, EUR J NUCL MED MOL I, V41, P2066, DOI 10.1007/s00259-014-2834-3
  55. Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817
  56. Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504
  57. Wang B, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0211-y
  58. WEISS LM, 1984, AM J SURG PATHOL, V8, P163, DOI 10.1097/00000478-198403000-00001
  59. West AN, 2007, CANCER RES, V67, P600, DOI 10.1158/0008-5472.CAN-06-3767
  60. Wieneke JA, 2003, AM J SURG PATHOL, V27, P867, DOI 10.1097/00000478-200307000-00001
  61. Wilkin F, 2000, J CLIN ENDOCR METAB, V85, P2048, DOI 10.1210/jc.85.5.2048

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICESP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HU
Artigos e Materiais de Revistas Científicas - LIM/14
Artigos e Materiais de Revistas Científicas - LIM/42
Carregar mais